Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi - LARVOL DELTA

Switching to Long-Acting Cabotegravir and Rilpivirine in Turkey: Perspectives from People Living with HIV in a Setting of Increasing HIV Incidence. (PubMed, Medicina (Kaunas)) - "Background and Objectives: Long-acting cabotegravir and rilpivirine (LA-CAB/RPV) offers an alternative to daily oral antiretroviral therapy (ART) for people living with HIV (PLWH). Addressing these patient-centered factors and logistical barriers may support the successful integration of long-acting therapies into routine HIV care. Future longer-interval agents may improve patient-centered acceptability."

Journal • Human Immunodeficiency Virus • Infectious Disease

Safety, Tolerability, and Metabolic Effects of Long-Acting Cabotegravir and Rilpivirine in HIV Care: A Comprehensive Review. (PubMed, Viruses) - "The use of long-acting cabotegravir and rilpivirine (LA CAB/RPV) is a novel approach to manage human immunodeficiency virus (HIV). Although real-world data are still emerging, they suggest similar trends, including a possible improvement in lipid profiles. Overall, LA CAB/RPV appears to be a safe, well-tolerated and effective treatment option, although longer-term follow-up is needed."

Journal • Review • Human Immunodeficiency Virus • Infectious Disease

Long-Acting Cabotegravir and Rilpivirine in Patients With HIV With Solid Organ Transplantation: A Case Series. (PubMed, Open Forum Infect Dis) - "The findings suggest that this approach may be a viable treatment option, reducing drug interactions while maintaining virological suppression. Further research with larger cohorts is needed to confirm these findings and establish guidelines for implementation in transplant recipients."

Journal • Human Immunodeficiency Virus • Infectious Disease • Solid Organ Transplantation • Transplantation • CD4

Reasons for choosing oral-lead-in versus direct-to-injection when switching to long-acting antiretroviral therapy in East and Southern Africa (IAS-HIV 2025) - P3 | "Product labels for LAI cabotegravir (CAB) and rilpivirine (RPV) in USA and Europe include an optional one-month oral-lead-in (OLI) prior to initiating injections, despite data from high-income settings demostrating the saftey of direct-to-injection (DTI). Preference for OLI versus DTI varied by country. Providing reassurance about safety and tolerability of CAB+RPV could increase DTI preference and simplify implementation in a public health setting."

Human Immunodeficiency Virus • Infectious Disease

More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents (clinicaltrials.gov) - P1/2 | N=168 | Completed | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting ➔ Completed

Trial completion • Human Immunodeficiency Virus • Infectious Disease

Impact of liver fibrosis on cabotegravir and rilpivirine long-acting plasma concentrations (EACS 2025) - No abstract available

Infectious Disease

Long-acting injectable cabotegravir/rilpivirine in young adults with perinatally acquired HIV. RELATIVITY cohort study (EACS 2025) - No abstract available

Clinical • Human Immunodeficiency Virus • Infectious Disease

Determinants of Discontinuation of Long-Acting Cabotegravir/Rilpivirine: A Cause-Specific Analysis from Real-World Data (EACS 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Infectious Disease

HOLA: Implementation of Out-of-HOspital Administration of the Long-Acting Cabotegravir+Rilpivirine (clinicaltrials.gov) - P4 | N=103 | Completed | Sponsor: Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | Active, not recruiting ➔ Completed

Trial completion • Human Immunodeficiency Virus • Infectious Disease

Long-acting injectable cabotegravir and rilpivirine outcomes in HIV individuals with stable treatment with dolutegravir and rilpivirine (EACS 2025) - No abstract available

Clinical • Human Immunodeficiency Virus • Infectious Disease

Patient-Reported Health and Virological Outcomes Among People with HIV Switching to Long-Acting Injectable Cabotegravir and Rilpivirine (LANTERN) (EACS 2025) - No abstract available

Clinical • Human Immunodeficiency Virus • Infectious Disease

Rapid virologic suppression with DTG/3TC facilitates early switch to CAB+RPV LA for treatment-naive people living with HIV: suppression phase outcomes from the Phase 3b VOLITION study (IAS-HIV 2025) - P3 | "Once-daily DTG/3TC achieved rapid virologic suppression in a diverse population of treatment-naive adults with HIV-1, confirming its high potency and providing a pathway to person-centered treatment, allowing people to choose an early switch to LA therapy of their own VOLITION."

P3 data • Human Immunodeficiency Virus • Infectious Disease

Real-world implementation of long-acting injectable cabotegravir and rilpivirine: healthcare providers' perspectives and experiences (EACS 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Infectious Disease

Selection of antiretroviral resistance in treatment-experienced PWH with virological failure while on B/F/TAF, DTG/3TC or CAB/RPV LA: Virostar 2.0 study (EACS 2025) - No abstract available

Infectious Disease

Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs (clinicaltrials.gov) - P2 | N=50 | Recruiting | Sponsor: Yale University | Trial completion date: Oct 2026 ➔ Oct 2025

Trial completion date • Human Immunodeficiency Virus • Infectious Disease

Hepatitis B Virus Reactivation in People Living with HIV Switching to Long Acting-Cabotegravir/Rilpivirine therapy: A Cohort Study Analysis (EACS 2025) - No abstract available

Hepatitis B • Human Immunodeficiency Virus • Infectious Disease

Long-acting cabotegravir and rilpivirine in adults with suboptimal HIV control in sub-Saharan Africa: the IMPALA trial 48-week results (IAS-HIV 2025) - P3 | "BACKGROUND: In sub-Saharan Africa, 1.3 million people taking oral antiretroviral therapy (ART) are not virally suppressed. In people with adherence challenges, CAB+RPV-LA was non-inferior to dolutegravir-based ART for viral suppression and CVF, and performed better when considering any VL >1000 copies/ml, which is relevant for HIV transmission risk. A strong preference for injectable therapy, indicates that CAB+RPV-LA may play a key role for specific populations in the public health approach."

Clinical • Late-breaking abstract • Human Immunodeficiency Virus • Infectious Disease

Real-world use of long-acting injectable cabotegravir and rilpivirine (LAI-CAB+RPV) in non-virally suppressed individuals: a systematic review of baseline characteristics, virological failure outcomes and discontinuations (EACS 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Review • Infectious Disease

Design and evaluation of next-generation HIV genotyping for detection of resistance mutations to 28 antiretroviral drugs across five major classes including lenacapavir. (PubMed, Clin Infect Dis) - "PHG demonstrates significant improvements over standard care HIV genotyping, offering deeper insights into LEN-resistance, minority variants, and cross-class resistance using a low-cost high-throughput portable sequencing technology and publicly available cloud computing."

Journal • Human Immunodeficiency Virus • Infectious Disease

Barriers and Facilitators of Implementation of the Non-Hospital-Based Administration of Long-Acting Cabotegravir Plus Rilpivirine in People with HIV: Qualitative Data from the HOLA Study. (PubMed, Viruses) - P=N/A, P4 | "Findings reveal five main factors to consider for implementation: operational and infrastructure adaptations, integrated management of human and organizational resources, need for coordination and follow-up, professional attitudes and work environment, and patient experience and patients' needs perceived by professionals. This study emphasizes the comprehensive operational and infrastructure adaptations, adequate staff training, and supportive professional environment required for the successful implementation of CAB+RPV LA, while considering patients' needs throughout the externalization process (trial registration number: NCT06643897)."

Journal • Human Immunodeficiency Virus • Infectious Disease

Long-acting cabotegravir and rilpivirine for the treatment of people with HIV: current landscape and challenges ahead. (PubMed, J Antimicrob Chemother) - "In summary, LAI CAB + RPV is a promising and well-tolerated option for maintaining virological suppression in routine care, with the potential to address important unmet needs across a broad spectrum of PWH. Ongoing studies will help define its optimal use and long-term benefits in real-world settings."

Journal • Human Immunodeficiency Virus • Infectious Disease

Reorganizing a HIV clinic in northern Italy for the implementation of Long-Acting Cabotegravir/Rilpivirine for HIV Treatment with limited resources (EACS 2025) - No abstract available

Human Immunodeficiency Virus • Infectious Disease

Real-World Utilization of Cabotegravir/Rilpivirine Long-Acting Injectable: An Observational Analysis of Adherence and Persistence using a Patient Support Program in Canada (EACS 2025) - No abstract available

Adherence • Clinical • Real-world • Real-world evidence • Infectious Disease

Reduction of immune- senescence in People with HIV (PWH) switching to long-acting injectable Cabotegravir plus Rilpivirine (EACS 2025) - No abstract available

Human Immunodeficiency Virus • Infectious Disease

Differences on Clinical and Virological Outcomes of Cabotegravir + Rilpivirine Long Acting between Men and Women in the Dat'AIDS Cohort (EACS 2025) - No abstract available

Clinical • Human Immunodeficiency Virus • Infectious Disease